ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009
Neuropeptide Y overexpression using recombinant adeno-associated viral vectors.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Nanoparticle-encapsulated neuropeptide Y provides robust seizure protection in SCN1A-derived epilepsy.Epilepsia · 2026Article
- Review
- Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management.CNS & neurological disorders drug targets · 2025Review
- Development of In Vivo Imaging Tools for Investigating Astrocyte Activation in Epileptogenesis.Molecular neurobiology · 2018Article
- Differential Effect of Neuropeptides on Excitatory Synaptic Transmission in Human Epileptic Hippocampus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models.Cancer gene therapy · 2014Article
- Neuropeptides as targets for the development of anticonvulsant drugs.Molecular neurobiology · 2014Review
- Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.Journal of molecular medicine (Berlin, Germany) · 2014Article
- Pathogenesis of epilepsy: challenges in animal models.Iranian journal of basic medical sciences · 2013Review
- Neuropeptide Y gene transfection inhibits post-epileptic hippocampal synaptic reconstruction.Neural regeneration research · 2013Article
- Fat grafting as a vehicle for the delivery of recombinant adenoassociated viral vectors to achieve gene modification of muscle flaps.Annals of plastic surgery · 2013Article
- Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats.Epilepsia · 2012Article
- RNAi: a potential new class of therapeutic for human genetic disease.Human genetics · 2011Review
- Article
- Differential regulation of vasoactive intestinal peptide (VIP) in the dentate gyrus and hippocampus via the NO-cGMP pathway following kainic acid-induced seizure in the rat.Journal of molecular neuroscience : MN · 2010Article
- Therapeutic potential of neuropeptide Y (NPY) receptor ligands.EMBO molecular medicine · 2010Review
- Review
- Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.Biochemical pharmacology · 2009Review
- Convection-enhanced delivery in the treatment of epilepsy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
Abstract
Gene therapy may represent a promising alternative treatment of epileptic patients who are resistant to conventional anti-epileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant adeno-associated viral (AAV) vectors have been most widely used. Preclinical studies using a selection of "therapeutic" genes injected into the rodent brain to correct the compromised balance between inhibitory and excitatory transmission in epilepsy, showed significant reduction of seizures and inhibition of epileptogenesis. In particular, transduction of neuropeptide genes, such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. Recent findings showed a long-lasting NPY over-expression in the rat hippocampus by local application of recombinant AAV vectors associated with reduced generalization of seizures, delayed kindling epileptogenesis, and strong reduction of chronic spontaneous seizures. These results establish a proof-of-principle evidence of the efficacy of gene therapy as anticonvulsant treatment. Additional investigations are required to address safety concerns and possible side effects in more detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.